Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Who Are The Key Players In The Inmazeb Market? Major players shaping the Inmazeb market include Regeneron Pharmaceuticals Inc. Industry transformations, innovative research and advancement in ...

Dr George D. Yancopoulos, Regeneron’s chief scientific officer, said: “We are honoured that the Galien Foundation has recognised Inmazeb […] Our ability to rapidly respond to Ebola was based ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Ebola belongs to a class of viruses called filoviruses, for which there are two U.S. approved human antibody drugs - Ebanga from Ridgeback Biotherapeutics and Inmazeb from Regeneron ...

As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.

Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your operator for today's call. At this time, all participants are ...

Regeneron posted Q4 adjusted EPS of $12.07, beating the $11.29 consensus. Sales rose 10% to $3.79B, surpassing the $3.75B estimates. Eylea HD and Eylea U.S. sales grew 2% Y/Y to $1.49B, while ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in ...